Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.54 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345475 | 0.89 | ACHE (0.51) | CYP24A1CYP26A1CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4622848 | 0.87 | CYP24A1 (0.58) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL7290713 | 0.87 | CYP24A1 (0.53) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL972021 | 0.87 | CYP24A1 (0.53) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL2466607 | 0.86 | METAP1 (0.53) | CYP24A1CYP26A1CYP19A1SMN1; SMN2KDM4E | |
| SCHEMBL5217220 | 0.85 | MAPK1 (0.53) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL9142321 | 0.83 | PIN1 (0.43) | CYP24A1CYP26A1CYP27A1KDM4ERAB9A | |
| SCHEMBL19900206 | 0.83 | SRD5A1 (0.42) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL8921424 | 0.83 | CYP24A1 (0.51) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 | |
| SCHEMBL4098450 | 0.83 | CYP24A1 (0.54) | CYP24A1CYP26A1CYP27A1CYP19A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2670245-B1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | SCRIPPS RESEARCH INST (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-5696143-A | ARTHRITIS THERAPY | G.D. SEARLE & CO. | 1997-12-09 | — | — | US | disclosed |
| WO-1996009293-A1 | BENZ[g]INDAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | CYP24A1 3919/4885CYP26A1 4235/4885CYP27A1 1061/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | CYP24A1 3919/4885CYP26A1 4235/4885CYP27A1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.